Drug Trial Radar · NCT00108004
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: May 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Planned (sponsor's estimate)
Start
Apr 2003
Primary completion
Jun 2005
Study completion Jun 2005
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.
Conditions
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Interventions
pramlintide acetateDrug
Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the clinical utility and safety of pramlintide in subjects with type 1 and type 2 diabetes mellitusTime frame: 6 months
- Understand management issues in subjects with type 1 and type 2 diabetes mellitusTime frame: 6 months
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Anaheim, California
Research Site
Escondido, California
Research Site
La Jolla, California
Research Site
Los Gatos, California
Research Site
San Francisco, California
Research Site
Torrance, California
Research Site
New Britain, Connecticut
Research Site
Norwalk, Connecticut
Research Site
Norwich, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Clearwater, Florida
Research Site
Orlando, Florida
Research Site
Columbus, Georgia
Research Site
Honolulu, Hawaii
Research Site
Idaho Falls, Idaho
Research Site
Indianapolis, Indiana
Research Site
Vincennes, Indiana
Research Site
Topeka, Kansas
Research Site
Wichita, Kansas
Research Site
Lexington, Kentucky
Research Site
Baltimore, Maryland
Research Site
Bloomfield Hills, Michigan
Research Site
Tupelo, Mississippi
Research Site
Las Vegas, Nevada
Research Site
Reno, Nevada
Research Site
Moorestown, New Jersey
Research Site
Neptune City, New Jersey
Research Site
Roseland, New Jersey
Research Site
New York, New York
Research Site
Williston Park, New York
Research Site
Yonkers, New York
Research Site
Greenville, North Carolina
Research Site
Lakewood, Ohio
Research Site
Westlake, Ohio
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Wilkes-Barre, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Sumter, South Carolina
Research Site
Chattanooga, Tennessee
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.